Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.
Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.
This report aims to provide a comprehensive presentation of the global market for Neuromyelitis Optica Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuromyelitis Optica Therapy. This report contains market size and forecasts of Neuromyelitis Optica Therapy in global, including the following market information:
Global Neuromyelitis Optica Therapy Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global top five companies in 2022 (%)
The global Neuromyelitis Optica Therapy market was valued at US$ 48 million in 2022 and is projected to reach US$ 61 million by 2029, at a CAGR of 3.3% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Europe is the largest Neuromyelitis Optica Drug market with about 40% market share. North America is follower, accounting for about 35% market share.
The key players are Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, Grifols, Octapharma, CBOP etc. Top 3 companies occupied about 35% market share.
We surveyed the Neuromyelitis Optica Therapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Neuromyelitis Optica Therapy Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Neuromyelitis Optica Therapy Market Segment Percentages, by Type, 2022 (%)
Glucocorticoids
Immunotherapies
Other
Global Neuromyelitis Optica Therapy Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Neuromyelitis Optica Therapy Market Segment Percentages, by Application, 2022 (%)
Acute Attack
Remission Prophylactic Treatment
Global Neuromyelitis Optica Therapy Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Neuromyelitis Optica Therapy Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Neuromyelitis Optica Therapy revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Neuromyelitis Optica Therapy revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
Fresenius
Teva
Sandoz
Intas
Gyjtrs
NANG KUANG
Tianjin Kingyork
Baxter
CSL
Grifols
Octapharma
CBOP
Outline of Major Chapters:
Chapter 1: Introduces the definition of Neuromyelitis Optica Therapy, market overview.
Chapter 2: Global Neuromyelitis Optica Therapy market size in revenue.
Chapter 3: Detailed analysis of Neuromyelitis Optica Therapy company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Neuromyelitis Optica Therapy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Neuromyelitis Optica Therapy Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Neuromyelitis Optica Therapy Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Neuromyelitis Optica Therapy Overall Market Size
2.1 Global Neuromyelitis Optica Therapy Market Size: 2022 VS 2030
2.2 Global Neuromyelitis Optica Therapy Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Neuromyelitis Optica Therapy Players in Global Market
3.2 Top Global Neuromyelitis Optica Therapy Companies Ranked by Revenue
3.3 Global Neuromyelitis Optica Therapy Revenue by Companies
3.4 Top 3 and Top 5 Neuromyelitis Optica Therapy Companies in Global Market, by Revenue in 2022
3.5 Global Companies Neuromyelitis Optica Therapy Product Type
3.6 Tier 1, Tier 2 and Tier 3 Neuromyelitis Optica Therapy Players in Global Market
3.6.1 List of Global Tier 1 Neuromyelitis Optica Therapy Companies
3.6.2 List of Global Tier 2 and Tier 3 Neuromyelitis Optica Therapy Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Neuromyelitis Optica Therapy Market Size Markets, 2022 & 2030
4.1.2 Glucocorticoids
4.1.3 Immunotherapies
4.1.4 Other
4.2 By Type - Global Neuromyelitis Optica Therapy Revenue & Forecasts
4.2.1 By Type - Global Neuromyelitis Optica Therapy Revenue, 2018-2023
4.2.2 By Type - Global Neuromyelitis Optica Therapy Revenue, 2024-2030
4.2.3 By Type - Global Neuromyelitis Optica Therapy Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Neuromyelitis Optica Therapy Market Size, 2022 & 2030
5.1.2 Acute Attack
5.1.3 Remission Prophylactic Treatment
5.2 By Application - Global Neuromyelitis Optica Therapy Revenue & Forecasts
5.2.1 By Application - Global Neuromyelitis Optica Therapy Revenue, 2018-2023
5.2.2 By Application - Global Neuromyelitis Optica Therapy Revenue, 2024-2030
5.2.3 By Application - Global Neuromyelitis Optica Therapy Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global Neuromyelitis Optica Therapy Market Size, 2022 & 2030
6.2 By Region - Global Neuromyelitis Optica Therapy Revenue & Forecasts
6.2.1 By Region - Global Neuromyelitis Optica Therapy Revenue, 2018-2023
6.2.2 By Region - Global Neuromyelitis Optica Therapy Revenue, 2024-2030
6.2.3 By Region - Global Neuromyelitis Optica Therapy Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America Neuromyelitis Optica Therapy Revenue, 2018-2030
6.3.2 US Neuromyelitis Optica Therapy Market Size, 2018-2030
6.3.3 Canada Neuromyelitis Optica Therapy Market Size, 2018-2030
6.3.4 Mexico Neuromyelitis Optica Therapy Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe Neuromyelitis Optica Therapy Revenue, 2018-2030
6.4.2 Germany Neuromyelitis Optica Therapy Market Size, 2018-2030
6.4.3 France Neuromyelitis Optica Therapy Market Size, 2018-2030
6.4.4 U.K. Neuromyelitis Optica Therapy Market Size, 2018-2030
6.4.5 Italy Neuromyelitis Optica Therapy Market Size, 2018-2030
6.4.6 Russia Neuromyelitis Optica Therapy Market Size, 2018-2030
6.4.7 Nordic Countries Neuromyelitis Optica Therapy Market Size, 2018-2030
6.4.8 Benelux Neuromyelitis Optica Therapy Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia Neuromyelitis Optica Therapy Revenue, 2018-2030
6.5.2 China Neuromyelitis Optica Therapy Market Size, 2018-2030
6.5.3 Japan Neuromyelitis Optica Therapy Market Size, 2018-2030
6.5.4 South Korea Neuromyelitis Optica Therapy Market Size, 2018-2030
6.5.5 Southeast Asia Neuromyelitis Optica Therapy Market Size, 2018-2030
6.5.6 India Neuromyelitis Optica Therapy Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America Neuromyelitis Optica Therapy Revenue, 2018-2030
6.6.2 Brazil Neuromyelitis Optica Therapy Market Size, 2018-2030
6.6.3 Argentina Neuromyelitis Optica Therapy Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Neuromyelitis Optica Therapy Revenue, 2018-2030
6.7.2 Turkey Neuromyelitis Optica Therapy Market Size, 2018-2030
6.7.3 Israel Neuromyelitis Optica Therapy Market Size, 2018-2030
6.7.4 Saudi Arabia Neuromyelitis Optica Therapy Market Size, 2018-2030
6.7.5 UAE Neuromyelitis Optica Therapy Market Size, 2018-2030
7 Neuromyelitis Optica Therapy Companies Profiles
7.1 Pfizer
7.1.1 Pfizer Company Summary
7.1.2 Pfizer Business Overview
7.1.3 Pfizer Neuromyelitis Optica Therapy Major Product Offerings
7.1.4 Pfizer Neuromyelitis Optica Therapy Revenue in Global Market (2018-2023)
7.1.5 Pfizer Key News & Latest Developments
7.2 Fresenius
7.2.1 Fresenius Company Summary
7.2.2 Fresenius Business Overview
7.2.3 Fresenius Neuromyelitis Optica Therapy Major Product Offerings
7.2.4 Fresenius Neuromyelitis Optica Therapy Revenue in Global Market (2018-2023)
7.2.5 Fresenius Key News & Latest Developments
7.3 Teva
7.3.1 Teva Company Summary
7.3.2 Teva Business Overview
7.3.3 Teva Neuromyelitis Optica Therapy Major Product Offerings
7.3.4 Teva Neuromyelitis Optica Therapy Revenue in Global Market (2018-2023)
7.3.5 Teva Key News & Latest Developments
7.4 Sandoz
7.4.1 Sandoz Company Summary
7.4.2 Sandoz Business Overview
7.4.3 Sandoz Neuromyelitis Optica Therapy Major Product Offerings
7.4.4 Sandoz Neuromyelitis Optica Therapy Revenue in Global Market (2018-2023)
7.4.5 Sandoz Key News & Latest Developments
7.5 Intas
7.5.1 Intas Company Summary
7.5.2 Intas Business Overview
7.5.3 Intas Neuromyelitis Optica Therapy Major Product Offerings
7.5.4 Intas Neuromyelitis Optica Therapy Revenue in Global Market (2018-2023)
7.5.5 Intas Key News & Latest Developments
7.6 Gyjtrs
7.6.1 Gyjtrs Company Summary
7.6.2 Gyjtrs Business Overview
7.6.3 Gyjtrs Neuromyelitis Optica Therapy Major Product Offerings
7.6.4 Gyjtrs Neuromyelitis Optica Therapy Revenue in Global Market (2018-2023)
7.6.5 Gyjtrs Key News & Latest Developments
7.7 NANG KUANG
7.7.1 NANG KUANG Company Summary
7.7.2 NANG KUANG Business Overview
7.7.3 NANG KUANG Neuromyelitis Optica Therapy Major Product Offerings
7.7.4 NANG KUANG Neuromyelitis Optica Therapy Revenue in Global Market (2018-2023)
7.7.5 NANG KUANG Key News & Latest Developments
7.8 Tianjin Kingyork
7.8.1 Tianjin Kingyork Company Summary
7.8.2 Tianjin Kingyork Business Overview
7.8.3 Tianjin Kingyork Neuromyelitis Optica Therapy Major Product Offerings
7.8.4 Tianjin Kingyork Neuromyelitis Optica Therapy Revenue in Global Market (2018-2023)
7.8.5 Tianjin Kingyork Key News & Latest Developments
7.9 Baxter
7.9.1 Baxter Company Summary
7.9.2 Baxter Business Overview
7.9.3 Baxter Neuromyelitis Optica Therapy Major Product Offerings
7.9.4 Baxter Neuromyelitis Optica Therapy Revenue in Global Market (2018-2023)
7.9.5 Baxter Key News & Latest Developments
7.10 CSL
7.10.1 CSL Company Summary
7.10.2 CSL Business Overview
7.10.3 CSL Neuromyelitis Optica Therapy Major Product Offerings
7.10.4 CSL Neuromyelitis Optica Therapy Revenue in Global Market (2018-2023)
7.10.5 CSL Key News & Latest Developments
7.11 Grifols
7.11.1 Grifols Company Summary
7.11.2 Grifols Business Overview
7.11.3 Grifols Neuromyelitis Optica Therapy Major Product Offerings
7.11.4 Grifols Neuromyelitis Optica Therapy Revenue in Global Market (2018-2023)
7.11.5 Grifols Key News & Latest Developments
7.12 Octapharma
7.12.1 Octapharma Company Summary
7.12.2 Octapharma Business Overview
7.12.3 Octapharma Neuromyelitis Optica Therapy Major Product Offerings
7.12.4 Octapharma Neuromyelitis Optica Therapy Revenue in Global Market (2018-2023)
7.12.5 Octapharma Key News & Latest Developments
7.13 CBOP
7.13.1 CBOP Company Summary
7.13.2 CBOP Business Overview
7.13.3 CBOP Neuromyelitis Optica Therapy Major Product Offerings
7.13.4 CBOP Neuromyelitis Optica Therapy Revenue in Global Market (2018-2023)
7.13.5 CBOP Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Neuromyelitis Optica Therapy Market Opportunities & Trends in Global Market
Table 2. Neuromyelitis Optica Therapy Market Drivers in Global Market
Table 3. Neuromyelitis Optica Therapy Market Restraints in Global Market
Table 4. Key Players of Neuromyelitis Optica Therapy in Global Market
Table 5. Top Neuromyelitis Optica Therapy Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Neuromyelitis Optica Therapy Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Neuromyelitis Optica Therapy Revenue Share by Companies, 2018-2023
Table 8. Global Companies Neuromyelitis Optica Therapy Product Type
Table 9. List of Global Tier 1 Neuromyelitis Optica Therapy Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Neuromyelitis Optica Therapy Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Neuromyelitis Optica Therapy Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Neuromyelitis Optica Therapy Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Neuromyelitis Optica Therapy Revenue in Global (US$, Mn), 2024-2030
Table 14. By Application ? Global Neuromyelitis Optica Therapy Revenue, (US$, Mn), 2022 & 2030
Table 15. By Application - Neuromyelitis Optica Therapy Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Neuromyelitis Optica Therapy Revenue in Global (US$, Mn), 2024-2030
Table 17. By Region ? Global Neuromyelitis Optica Therapy Revenue, (US$, Mn), 2022 & 2030
Table 18. By Region - Global Neuromyelitis Optica Therapy Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Neuromyelitis Optica Therapy Revenue (US$, Mn), 2024-2030
Table 20. By Country - North America Neuromyelitis Optica Therapy Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Neuromyelitis Optica Therapy Revenue, (US$, Mn), 2024-2030
Table 22. By Country - Europe Neuromyelitis Optica Therapy Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Neuromyelitis Optica Therapy Revenue, (US$, Mn), 2024-2030
Table 24. By Region - Asia Neuromyelitis Optica Therapy Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Neuromyelitis Optica Therapy Revenue, (US$, Mn), 2024-2030
Table 26. By Country - South America Neuromyelitis Optica Therapy Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Neuromyelitis Optica Therapy Revenue, (US$, Mn), 2024-2030
Table 28. By Country - Middle East & Africa Neuromyelitis Optica Therapy Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Neuromyelitis Optica Therapy Revenue, (US$, Mn), 2024-2030
Table 30. Pfizer Company Summary
Table 31. Pfizer Neuromyelitis Optica Therapy Product Offerings
Table 32. Pfizer Neuromyelitis Optica Therapy Revenue (US$, Mn) & (2018-2023)
Table 33. Pfizer Key News & Latest Developments
Table 34. Fresenius Company Summary
Table 35. Fresenius Neuromyelitis Optica Therapy Product Offerings
Table 36. Fresenius Neuromyelitis Optica Therapy Revenue (US$, Mn) & (2018-2023)
Table 37. Fresenius Key News & Latest Developments
Table 38. Teva Company Summary
Table 39. Teva Neuromyelitis Optica Therapy Product Offerings
Table 40. Teva Neuromyelitis Optica Therapy Revenue (US$, Mn) & (2018-2023)
Table 41. Teva Key News & Latest Developments
Table 42. Sandoz Company Summary
Table 43. Sandoz Neuromyelitis Optica Therapy Product Offerings
Table 44. Sandoz Neuromyelitis Optica Therapy Revenue (US$, Mn) & (2018-2023)
Table 45. Sandoz Key News & Latest Developments
Table 46. Intas Company Summary
Table 47. Intas Neuromyelitis Optica Therapy Product Offerings
Table 48. Intas Neuromyelitis Optica Therapy Revenue (US$, Mn) & (2018-2023)
Table 49. Intas Key News & Latest Developments
Table 50. Gyjtrs Company Summary
Table 51. Gyjtrs Neuromyelitis Optica Therapy Product Offerings
Table 52. Gyjtrs Neuromyelitis Optica Therapy Revenue (US$, Mn) & (2018-2023)
Table 53. Gyjtrs Key News & Latest Developments
Table 54. NANG KUANG Company Summary
Table 55. NANG KUANG Neuromyelitis Optica Therapy Product Offerings
Table 56. NANG KUANG Neuromyelitis Optica Therapy Revenue (US$, Mn) & (2018-2023)
Table 57. NANG KUANG Key News & Latest Developments
Table 58. Tianjin Kingyork Company Summary
Table 59. Tianjin Kingyork Neuromyelitis Optica Therapy Product Offerings
Table 60. Tianjin Kingyork Neuromyelitis Optica Therapy Revenue (US$, Mn) & (2018-2023)
Table 61. Tianjin Kingyork Key News & Latest Developments
Table 62. Baxter Company Summary
Table 63. Baxter Neuromyelitis Optica Therapy Product Offerings
Table 64. Baxter Neuromyelitis Optica Therapy Revenue (US$, Mn) & (2018-2023)
Table 65. Baxter Key News & Latest Developments
Table 66. CSL Company Summary
Table 67. CSL Neuromyelitis Optica Therapy Product Offerings
Table 68. CSL Neuromyelitis Optica Therapy Revenue (US$, Mn) & (2018-2023)
Table 69. CSL Key News & Latest Developments
Table 70. Grifols Company Summary
Table 71. Grifols Neuromyelitis Optica Therapy Product Offerings
Table 72. Grifols Neuromyelitis Optica Therapy Revenue (US$, Mn) & (2018-2023)
Table 73. Grifols Key News & Latest Developments
Table 74. Octapharma Company Summary
Table 75. Octapharma Neuromyelitis Optica Therapy Product Offerings
Table 76. Octapharma Neuromyelitis Optica Therapy Revenue (US$, Mn) & (2018-2023)
Table 77. Octapharma Key News & Latest Developments
Table 78. CBOP Company Summary
Table 79. CBOP Neuromyelitis Optica Therapy Product Offerings
Table 80. CBOP Neuromyelitis Optica Therapy Revenue (US$, Mn) & (2018-2023)
Table 81. CBOP Key News & Latest Developments
List of Figures
Figure 1. Neuromyelitis Optica Therapy Segment by Type in 2022
Figure 2. Neuromyelitis Optica Therapy Segment by Application in 2022
Figure 3. Global Neuromyelitis Optica Therapy Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Neuromyelitis Optica Therapy Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Neuromyelitis Optica Therapy Revenue, 2018-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Neuromyelitis Optica Therapy Revenue in 2022
Figure 8. By Type - Global Neuromyelitis Optica Therapy Revenue Market Share, 2018-2030
Figure 9. By Application - Global Neuromyelitis Optica Therapy Revenue Market Share, 2018-2030
Figure 10. By Type - Global Neuromyelitis Optica Therapy Revenue, (US$, Mn), 2022 & 2030
Figure 11. By Type - Global Neuromyelitis Optica Therapy Revenue Market Share, 2018-2030
Figure 12. By Application - Global Neuromyelitis Optica Therapy Revenue, (US$, Mn), 2022 & 2030
Figure 13. By Application - Global Neuromyelitis Optica Therapy Revenue Market Share, 2018-2030
Figure 14. By Region - Global Neuromyelitis Optica Therapy Revenue Market Share, 2018-2030
Figure 15. By Country - North America Neuromyelitis Optica Therapy Revenue Market Share, 2018-2030
Figure 16. US Neuromyelitis Optica Therapy Revenue, (US$, Mn), 2018-2030
Figure 17. Canada Neuromyelitis Optica Therapy Revenue, (US$, Mn), 2018-2030
Figure 18. Mexico Neuromyelitis Optica Therapy Revenue, (US$, Mn), 2018-2030
Figure 19. By Country - Europe Neuromyelitis Optica Therapy Revenue Market Share, 2018-2030
Figure 20. Germany Neuromyelitis Optica Therapy Revenue, (US$, Mn), 2018-2030
Figure 21. France Neuromyelitis Optica Therapy Revenue, (US$, Mn), 2018-2030
Figure 22. U.K. Neuromyelitis Optica Therapy Revenue, (US$, Mn), 2018-2030
Figure 23. Italy Neuromyelitis Optica Therapy Revenue, (US$, Mn), 2018-2030
Figure 24. Russia Neuromyelitis Optica Therapy Revenue, (US$, Mn), 2018-2030
Figure 25. Nordic Countries Neuromyelitis Optica Therapy Revenue, (US$, Mn), 2018-2030
Figure 26. Benelux Neuromyelitis Optica Therapy Revenue, (US$, Mn), 2018-2030
Figure 27. By Region - Asia Neuromyelitis Optica Therapy Revenue Market Share, 2018-2030
Figure 28. China Neuromyelitis Optica Therapy Revenue, (US$, Mn), 2018-2030
Figure 29. Japan Neuromyelitis Optica Therapy Revenue, (US$, Mn), 2018-2030
Figure 30. South Korea Neuromyelitis Optica Therapy Revenue, (US$, Mn), 2018-2030
Figure 31. Southeast Asia Neuromyelitis Optica Therapy Revenue, (US$, Mn), 2018-2030
Figure 32. India Neuromyelitis Optica Therapy Revenue, (US$, Mn), 2018-2030
Figure 33. By Country - South America Neuromyelitis Optica Therapy Revenue Market Share, 2018-2030
Figure 34. Brazil Neuromyelitis Optica Therapy Revenue, (US$, Mn), 2018-2030
Figure 35. Argentina Neuromyelitis Optica Therapy Revenue, (US$, Mn), 2018-2030
Figure 36. By Country - Middle East & Africa Neuromyelitis Optica Therapy Revenue Market Share, 2018-2030
Figure 37. Turkey Neuromyelitis Optica Therapy Revenue, (US$, Mn), 2018-2030
Figure 38. Israel Neuromyelitis Optica Therapy Revenue, (US$, Mn), 2018-2030
Figure 39. Saudi Arabia Neuromyelitis Optica Therapy Revenue, (US$, Mn), 2018-2030
Figure 40. UAE Neuromyelitis Optica Therapy Revenue, (US$, Mn), 2018-2030
Figure 41. Pfizer Neuromyelitis Optica Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Fresenius Neuromyelitis Optica Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Teva Neuromyelitis Optica Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Sandoz Neuromyelitis Optica Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Intas Neuromyelitis Optica Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Gyjtrs Neuromyelitis Optica Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. NANG KUANG Neuromyelitis Optica Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Tianjin Kingyork Neuromyelitis Optica Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Baxter Neuromyelitis Optica Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. CSL Neuromyelitis Optica Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Grifols Neuromyelitis Optica Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Octapharma Neuromyelitis Optica Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 53. CBOP Neuromyelitis Optica Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
